Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497600 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01497600 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 50 participants.
The verdict
NCT01497600, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.
Interventions
- DRUG insulin NPH
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-02 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497600
The ClinicalTrials.gov registry entry for NCT01497600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin NPH is the first listed.
NCT01497600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497600 about?
NCT01497600 is a clinical study titled "Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes". This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.
What is the current status of trial NCT01497600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2004-02. Estimated completion is 2004-08.
What interventions are being tested in trial NCT01497600?
The interventions under investigation include: insulin NPH (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT01497600?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.